Biologics - beyond the joints

Area of Science:

• Rheumatology
• Immunology
• Pharmacology

Background:

• Biologic agents, including tumor necrosis factor α (TNF-α), interleukin-6 receptor (IL-6R), and T/B cell inhibitors, are established treatments for arthritis.
• These therapies significantly improve articular symptoms and prevent joint destruction.
• Arthritis often presents with extra-articular manifestations (EAMs) such as uveitis, inflammatory bowel disease, psoriasis, bone loss, and cardiovascular disease.

Purpose of the Study:

• To review the current understanding of biologic therapies for arthritis.
• To explore potential differences in the efficacy of various biologics, including TNF inhibitors, rituximab, and tocilizumab, in managing EAMs.
• To identify the need for further evidence regarding these differences.

Main Methods:

• Literature review of existing studies on biologic treatments for arthritis and their effects on EAMs.
• Analysis of data suggesting differential impacts of specific biologics on systemic manifestations.
• Identification of knowledge gaps requiring further investigation.

Main Results:

• Available biologics demonstrate comparable efficacy in improving articular symptoms and inhibiting joint damage.
• Emerging data suggest potential variations in how different biologics (e.g., TNF inhibitors, rituximab, tocilizumab) affect EAMs.
• Current evidence is insufficient to definitively confirm these observed differences in EAM management.

Conclusions:

• While biologics are effective for joint disease in arthritis, their differential effects on systemic manifestations require further investigation.
• Large-scale clinical trials and long-term observational studies are necessary to elucidate these potential differences.
• Understanding these nuances is crucial for optimizing treatment strategies for patients with complex arthritis presentations.